Exploring the Business Case for Longevity

In this episode, Omri Amirav-Drory (NFX), Joe Betts-LaCroix (Retro Bio), and Alex Colville (Age1) discuss the history, recent progress, and hurdles in the longevity industry, including the evaluation of potential founders and business risks. The discussion further encompasses the global fundraising potential and societal impact of the longevity sector, viewing aging as a disease, and the future of longevity drugs. Learn more at - https://nfx.com/bio (0:00) Introduction and Overview of Longevity Science (4:21) Transition from Scientist to Investor: Alex Colville's Journey (8:16) Current Advancements in Biology and Aging Field (12:15) Cutting Edge Topics in Longevity Space (20:02) Evaluating Potential Founders and Startups in the Longevity Space (22:08) Challenges in Longevity Field: FDA Approval and Mission Focus (23:46) Risks and Investment in the Biotech Industry (27:24) Misconceptions and Business Case for Longevity (32:34) Societal Effects and Impact of Longevity Drugs (36:08) Advice and Future Challenges for Founders in the Longevity Field (38:04) Closing Remarks and Thanks